Source comparison
The Receptor Pathways: GHRH Amplification Versus Ghrelin Mimicry
CJC-1295 no DAC belongs to the growth hormone-releasing hormone analog class—specifically, it's a modified version of GHRH(1-29) with four amino acid substitutions that extend its half-life from under 7 minutes to approximately 30 minutes while preserving rece
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC belongs to the growth hormone-releasing hormone analog class—specifically, it's a modified version of GHRH(1-29) with four amino acid substitutions that extend its half-life from under 7 minutes to approximately 30 minutes while preserving receptor selectivity. The compound binds to GHRH receptors on pituitary somatotroph cells, triggering a G-protein-coupled signaling cascade that increases intracellular cAMP and activates protein kinase A (PKA). This pathway ultimately opens voltage-gated calcium channels, allowing calcium influx that triggers vesicular release of stored growth hormone into systemic circulation.
- What makes CJC-1295 no DAC different from synthetic GHRH or even CJC-1295 with DAC (Drug Affinity Complex) is the duration of receptor occupancy. Without the DAC modification—a reactive chemical group that binds to serum albumin and extends half-life to 6–8 days—the 'no DAC' version maintains a half-life of roughly 30 minutes. This shorter half-life allows researchers to control pulsatile timing more precisely, mirroring the natural ultradian rhythm of GH secretion that occurs in 8–12 pulses per 24-hour cycle in physiological models.
- Ipamorelin operates through an entirely different mechanism. It's a pentapeptide (five amino acids) that acts as a selective agonist at the GHS-R1a receptor, the same receptor activated by the endogenous hormone ghrelin. Ghrelin is primarily produced in the stomach and signals hunger, but GHS-R1a receptors are densely expressed in the pituitary, where their activation triggers GH release independent of GHRH signaling. Ipamorelin's selectivity is its defining characteristic—unlike earlier ghrelin mimetics such as GHRP-6 or GHRP-2, Ipamorelin doesn't significantly activate receptors for cortisol, prolactin, or acetylcholine, meaning it stimulates GH release without elevating stress hormones or appetite signaling in most research models.
- The half-life of Ipamorelin is approximately 2 hours, which is longer than CJC-1295 no DAC but still short enough to produce discrete GH pulses rather than sustained elevation. Peak plasma GH concentration occurs 30–45 minutes post-injection in subcutaneous administration models, with levels returning to baseline within 3–4 hours. This pulsatility is critical—chronic supraphysiological GH elevation leads to receptor desensitization and negative feedback activation, whereas pulsatile release preserves downstream signaling sensitivity at IGF-1 target tissues including liver, muscle, and bone.
- When CJC-1295 no DAC and Ipamorelin are co-administered, the result is receptor pathway synergy: GHRH receptor stimulation primes the somatotrophs, increasing their responsiveness to subsequent signals, while ghrelin receptor activation provides that signal in a manner that bypasses somatostatin's inhibitory tone. The net effect is GH pulse amplitude 2.5–4 times higher than either peptide alone, as demonstrated in multiple preclinical models measuring plasma GH via enzyme-linked immunosorbent assay (ELISA).